- Home
- BJRI vs CTMX Comparison
BJRI vs CTMX Comparison
Compare BJRI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- CTMX
- Stock Information
- Founded
- BJRI 1978
- CTMX 2008
- Country
- BJRI United States
- CTMX United States
- Employees
- BJRI N/A
- CTMX N/A
- Industry
- BJRI Restaurants
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- CTMX Health Care
- Exchange
- BJRI Nasdaq
- CTMX Nasdaq
- Market Cap
- BJRI 706.6M
- CTMX 596.2M
- IPO Year
- BJRI 1996
- CTMX 2015
- Fundamental
- Price
- BJRI $36.06
- CTMX $4.04
- Analyst Decision
- BJRI Buy
- CTMX Strong Buy
- Analyst Count
- BJRI 6
- CTMX 5
- Target Price
- BJRI $37.67
- CTMX $5.80
- AVG Volume (30 Days)
- BJRI 532.3K
- CTMX 3.5M
- Earning Date
- BJRI 10-30-2025
- CTMX 11-06-2025
- Dividend Yield
- BJRI N/A
- CTMX N/A
- EPS Growth
- BJRI 6.21
- CTMX 50.22
- EPS
- BJRI 1.34
- CTMX 0.24
- Revenue
- BJRI $1,388,066,000.00
- CTMX $113,631,000.00
- Revenue This Year
- BJRI $5.14
- CTMX N/A
- Revenue Next Year
- BJRI $2.80
- CTMX N/A
- P/E Ratio
- BJRI $26.11
- CTMX $15.11
- Revenue Growth
- BJRI 3.85
- CTMX N/A
- 52 Week Low
- BJRI $28.46
- CTMX $0.40
- 52 Week High
- BJRI $47.02
- CTMX $4.62
- Technical
- Relative Strength Index (RSI)
- BJRI 64.55
- CTMX 63.62
- Support Level
- BJRI $34.35
- CTMX $3.35
- Resistance Level
- BJRI $36.15
- CTMX $4.62
- Average True Range (ATR)
- BJRI 1.42
- CTMX 0.33
- MACD
- BJRI 0.52
- CTMX 0.03
- Stochastic Oscillator
- BJRI 92.78
- CTMX 66.67
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.